BusinessHealthWorld

The Projected CAGR For Osteoarthritis Treatment Market To Be 4.8% Between 2025

Osteoarthritis Treatment Market

The Osteoarthritis Treatment Market Share is slated to reach US$ 11,618.6 Million at a CAGR of 4.8% from 2025. In the era of digitization, healthcare content marketing is the epicenter. Healthcare-related videos and various healthcare product demos would be one of the trends shortly. Research states that more than 409 Mn people happen to read over 20 Bn pages every month.

Persistence Market Research (PMR) has published a new research report on the osteoarthritis treatment market titled “Osteoarthritis Treatment Market: Global Industry Analysis (2012-2016) and Forecast (2017-2025).” An alarming rise in the number of osteoarthritis cases is the result of a growing geriatric population worldwide. In order to cater to the needs of the rapidly increasing geriatric population as well as the female population – given that osteoarthritis prevails mostly among these groups – the manufacturers of osteoarthritis drugs are focusing on research and development to be able to develop better and reliable drugs.

As this disease is not treatable, the market is an ever growing one. In this run, the leading companies are also collaborating with other big companies in order to use their formulas and production equipment.

Get Going With Sample Of Osteoarthritis Market Report! https://www.persistencemarketresearch.co/samples/4458

Company Profiles

  • Pfizer Inc.
  • Johnson & Johnson Services, Inc.
  • Novartis AG
  • GlaxoSmithKline plc.
  • Zimmer Biomet Holdings, Inc.
  • Stryker Corporation
  • Abbott Laboratories

How About Re-Inventing The Methodical Wheel In The Osteoarthritis Market? Switch Over To The “Methodology” Tab! https://www.persistencemarketresearch.co/methodology/4458

For instance, in September 2016, Pfizer Inc. completed the acquisition of Medivation, Inc., a biopharmaceutical company focused on the development and commercialization of medically innovative therapies to treat serious diseases that have limited treatment options.

In this regard, the company also acquired the commercialization and development rights of the late stage small molecules anti-infective business, mainly outside the U.S. from AstraZeneca. Other companies operating in the market are Johnson & Johnson Services, Inc., Novartis AG, GlaxoSmithKline plc. Abbott Laboratories, and Zimmer Biomet Holdings, Inc., among others.

According to the report, the global osteoarthritis treatment market is expected to register a CAGR of 4.8% from 2017 to 2025. In 2017, the market was valued at US$ 7,969.7 Mn and is expected to rise to a valuation of US$ 11,618.6 Mn by the end of 2025.

Growing Geriatric Population and Rising Prevalence of Disease to Trigger Adoption

The prevalence of osteoarthritis is increasing across the globe and it is the major cause of disability, especially among the ageing population. Women are more likely to be affected than men and the prevalence rate progresses with age. Increasing awareness regarding the risk factors associated with osteoarthritis (such as obesity) among the general population due to government action plans to control the disease is expected to boost the growth of the osteoarthritis treatment market.

However, improvement in healthcare policies in various countries such as the U.S. has resulted in enhanced affordability for various diagnostic and treatment services, which in turn has increased the life expectancy of people. Other dynamics such as the availability of alternative medicines are expected to boost the growth of the market.

Keeping A Tab On Key Players In The Osteoarthritis Market? Go To “Purchase Now” To Decipher The Competitive Analysis In Our Osteoarthritis Market Report! https://www.persistencemarketresearch.com/checkout/4458

Non-availability of Permanent Cure for Osteoarthritis to Restrict Market Growth

Presently, there is no cure of osteoarthritis but the treatment is aimed to manage the symptoms. Aspects such as lack of awareness regarding risk factors and symptoms of osteoarthritis is expected to restrain the growth of the osteoarthritis treatment market.

There is no simple diagnosis available for osteoarthritis. Diagnosis is based on a variable combination of patient reported symptoms and imaging of the joint. Mostly x-ray is used to diagnose osteoarthritis, but it often does not correlate with other symptoms of osteoarthritis including joint pain.

About Us :-

Persistence Market Research is here to provide companies a one-stop solution with regards to bettering customer experience. It does engage in gathering appropriate feedback after getting through personalized customer interactions for adding value to customers’ experience by acting as the “missing” link between “customer relationships” and “business outcomes’. The best possible returns are assured therein.

Contact us:

Persistence Market Research
Address – 305 Broadway, 7th FloorNew York City,
NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com
Website – https://www.persistencemarketresearch.com

Back to top button